Open Access
Open access
Springer Nature
BMC Cancer
,  volume 23 ,  issue 1 ,  publication number 68

Biomarker analysis for patients with pancreatic cancer treated with nanoliposomal irinotecan plus 5-fluorouracil/leucovorin

Takeshi Kawakami 1
, 
Akiko Todaka 1
, 
Kotoe Oshima 1
, 
Kunihiro Fushiki 1
, 
Satoshi Hamauchi 1
, 
Takahiro Tsushima 1
, 
Tomoya Yokota 1
, 
Yusuke Onozawa 2
, 
Hirofumi Yasui 1
, 
Kentaro Yamazaki 1
1
 
2
 
Publication type: Journal Article
Publication date: 2023-01-20
Springer Nature
scimago Q2
wos Q2
SJR: 1.178
CiteScore: 5.7
Impact factor: 3.4
ISSN: 14712407
Cancer Research
Oncology
Genetics
Abstract
Background

Nanoliposomal irinotecan plus fluorouracil/leucovorin (5-FU/LV) is a standard second-line therapy for patients with pancreatic cancer. Identification of biomarkers is important to determine appropriate treatment strategies. We investigated the clinical practice outcomes and biomarkers associated with the nanoliposomal irinotecan plus 5-FU/LV regimen.

Methods

We retrospectively reviewed the data of patients treated with nanoliposomal irinotecan plus 5-FU/LV as a second or subsequent treatment after gemcitabine-based therapy between June 2020 and March 2021 at Shizuoka Cancer Center.

Results

We analyzed 55 consecutive patients who met the selection criteria. At a median of 9.4 months, median progression-free survival (PFS) and median overall survival (OS) were 2.3 and 6.6 months, respectively. Multivariate analysis showed that Glasgow prognostic score (GPS) was significantly associated with PFS (hazard ratio [HR] 2.16; 95% confidence interval [CI] 1.09–4.30; P = 0.028) and OS (0 vs. 1 or 2: HR 2.46; 95% CI 1.15–5.25; P = 0.029). The OS was significantly longer in patients with CA19–9 response than in those without CA19–9 response (12.6 vs. 5.6 months; HR 0.24; 95% CI 0.08–0.75; P = 0.014).

Conclusions

Nanoliposomal irinotecan was efficacious and tolerable in clinical practice. GPS and CA19–9 response were good candidates as predictive biomarkers, whereas GPS was a good candidate prognostic biomarker for the nanoliposomal irinotecan plus 5-FU/LV regimen.

Found 
Found 

Top-30

Journals

1
Journal of Clinical Medicine
Journal of Clinical Medicine, 1, 16.67%
Journal of Clinical Medicine
1 publication, 16.67%
Pancreatology
Pancreatology, 1, 16.67%
Pancreatology
1 publication, 16.67%
Scientific Reports
Scientific Reports, 1, 16.67%
Scientific Reports
1 publication, 16.67%
Frontiers in Microbiology
Frontiers in Microbiology, 1, 16.67%
Frontiers in Microbiology
1 publication, 16.67%
Gland Surgery
Gland Surgery, 1, 16.67%
Gland Surgery
1 publication, 16.67%
International Journal of Biological Macromolecules
International Journal of Biological Macromolecules, 1, 16.67%
International Journal of Biological Macromolecules
1 publication, 16.67%
1

Publishers

1
2
Elsevier
Elsevier, 2, 33.33%
Elsevier
2 publications, 33.33%
MDPI
MDPI, 1, 16.67%
MDPI
1 publication, 16.67%
Springer Nature
Springer Nature, 1, 16.67%
Springer Nature
1 publication, 16.67%
Frontiers Media S.A.
Frontiers Media S.A., 1, 16.67%
Frontiers Media S.A.
1 publication, 16.67%
AME Publishing Company
AME Publishing Company, 1, 16.67%
AME Publishing Company
1 publication, 16.67%
1
2
  • We do not take into account publications without a DOI.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
6
Share
Cite this
GOST |
Cite this
GOST Copy
Kawakami T. et al. Biomarker analysis for patients with pancreatic cancer treated with nanoliposomal irinotecan plus 5-fluorouracil/leucovorin // BMC Cancer. 2023. Vol. 23. No. 1. 68
GOST all authors (up to 50) Copy
Kawakami T., Todaka A., Oshima K., Fushiki K., Hamauchi S., Tsushima T., Yokota T., Onozawa Y., Yasui H., Yamazaki K. Biomarker analysis for patients with pancreatic cancer treated with nanoliposomal irinotecan plus 5-fluorouracil/leucovorin // BMC Cancer. 2023. Vol. 23. No. 1. 68
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.1186/s12885-023-10542-w
UR - https://doi.org/10.1186/s12885-023-10542-w
TI - Biomarker analysis for patients with pancreatic cancer treated with nanoliposomal irinotecan plus 5-fluorouracil/leucovorin
T2 - BMC Cancer
AU - Kawakami, Takeshi
AU - Todaka, Akiko
AU - Oshima, Kotoe
AU - Fushiki, Kunihiro
AU - Hamauchi, Satoshi
AU - Tsushima, Takahiro
AU - Yokota, Tomoya
AU - Onozawa, Yusuke
AU - Yasui, Hirofumi
AU - Yamazaki, Kentaro
PY - 2023
DA - 2023/01/20
PB - Springer Nature
IS - 1
VL - 23
PMID - 36670426
SN - 1471-2407
ER -
BibTex
Cite this
BibTex (up to 50 authors) Copy
@article{2023_Kawakami,
author = {Takeshi Kawakami and Akiko Todaka and Kotoe Oshima and Kunihiro Fushiki and Satoshi Hamauchi and Takahiro Tsushima and Tomoya Yokota and Yusuke Onozawa and Hirofumi Yasui and Kentaro Yamazaki},
title = {Biomarker analysis for patients with pancreatic cancer treated with nanoliposomal irinotecan plus 5-fluorouracil/leucovorin},
journal = {BMC Cancer},
year = {2023},
volume = {23},
publisher = {Springer Nature},
month = {jan},
url = {https://doi.org/10.1186/s12885-023-10542-w},
number = {1},
pages = {68},
doi = {10.1186/s12885-023-10542-w}
}